Navigation Links
NIH to fund collaborations with industry to identify new uses for existing compounds
Date:6/18/2013

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia. The collaborative pilot initiative, called Discovering New Therapeutic Uses for Existing Molecules, is led by the National Center for Advancing Translational Sciences (NCATS) and funded by the NIH Common Fund.

The process of developing a new therapeutic is long and difficult. The average length of time from target discovery to approval of a new drug is more than 13 years, and the failure rate exceeds 95 percent. This failure rate means, however, that many existing partially developed compounds could be advanced to clinical trials more quickly than starting from scratch.

"With thousands of diseases remaining untreatable, there is a sense of urgency to accelerate the pace at which discoveries are transformed into therapies for patients," said Health and Human Services Secretary Kathleen Sebelius. "This program helps forge partnerships between the pharmaceutical industry and the biomedical research community to work together to tackle problems that are beyond the scope of any one organization or sector."

"Innovative, collaborative approaches that improve the therapeutic pipeline are crucial for success," said NIH Director Francis S. Collins, M.D., Ph.D. "This unique collaboration between academia and industry holds the promise of trimming years from the long and expensive process of drug development."

AbbVie (formerly Abbott); AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Research & Development, LLC; Pfizer; and Sanofi are participating in the pilot phase of the program.

NCATS launched this initiative in 2012 to help re-engineer the research pipeline using an innovative strategy to ident
'/>"/>

Contact: NCATS Office of Communications
ncatsinfo@mail.nih.gov
301-435-0888
NIH/National Center for Advancing Translational Sciences (NCATS)
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. NREL teams with Navy, private industry to make jet fuel from switchgrass
2. Maps developed to help forest industry outwit climate change
3. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award
4. RAFT polymerization technology enabling the biotech industry
5. Medbox Positions Itself as the Leader on Wall Street in the Legalized Marijuana Industry
6. Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals
7. NREL employees lauded by industry peers
8. NREL assembles industry working group to advance solar securitization
9. Global Fingerprint Biometrics Industry
10. Global Hand Geometry Industry
11. Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... A mother,s iron deficiency early in pregnancy may have ... the child, even if the lack of iron is not ... Rochester Medical Center study published in the scientific journal ... might not notice or treat mild or moderate iron deficiency, ...
... 2011) - An animal,s behavior is probably its ... Its behavior involves processes internal to the animalgenetics, neurobiology, ... social surroundings. According to the book,s authors, "Animal behavior ... sparked when neurons fire in response to stimuli in ...
... In recent years, researchers have worked to develop more ... in Afghanistan or Iraq with missing arms or legs. ... entering the body through the space where the device ... area) where the bacteria would enter the body, and ...
Cached Biology News:Pre-conception and early pregnancy iron deficiency harms brain 2Pre-conception and early pregnancy iron deficiency harms brain 3New book on animal behavior provides integrated view 2Nanomodified surfaces seal leg implants against infection 2
(Date:4/23/2015)... Prospects for Leading Companies in ... Details   We predict the global healthcare ... in 2015 and will grow at a CAGR of 6.3% ... around the world and increasing functional requirements for healthcare packaging ... global healthcare packaging market. A global ageing population, ...
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... , April 23, 2015  Propanc Health Group ... company, focuses on the development of cancer treatments ... company lead product includes PRP, a patented formulation ... chymotrypsinogen, as well as the enzyme amylase designed ... developing a combination of anti-cancer agents working in ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) precisely measure ... in real time, and this data is uploaded to ... Machine to Machine (M2M) communications for the Internet of ... can be monitored by a patient’s clinician 24/7, ... a minimum threshold, the patient can be notified immediately. ...
Breaking Biology Technology:Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... Nov. 20 Amicus Therapeutics,(Nasdaq: FOLD ) today ... will present a corporate update at the Lazard Capital,Markets ... Tuesday,November 27th at 11:30 am ET at The New ... of the presentation will be available to all,interested parties ...
... Massachusetts and RAMBOUILLET, France,November 20 ... model-based,vision software for musculoskeletal radiography, and ... High Resolution Digital Radiology for osteoarticular,imaging, ... joint and bone,tissues, announced today the ...
... Completion of Strategic Acquisition Reflected in Q3 Results, ... Board: ECTE) today announced financial results for the,third quarter ... 30,2007, net loss was $8,677,000 or $.70 per share, ... period in 2006. For the nine months ended,September 30, ...
Cached Biology Technology:Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3Rapid Quantification of Osteoarthritis With a Novel, Office-Based, High-Resolution Digital Imaging Device 2Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Phosphorylase 1 ( Abpromise for all ... Synthetic peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF ... amino acids 1-99 of Human Uridine Phosphorylase ... 7378 Swiss Protein ...
Request Info...
Lingo-1 (K-13)...
Biology Products: